en · de · es · fr · pt
creatine-notes.peptides6908.com › Blog › Receptor Action And Clearance — Research Overview

Receptor Action And Clearance — Research Overview

By Editorial Desk · published 2025-09-23 · last reviewed 2025-10-07 · Blog

Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-10-07. Where a claim depends on a specific study, the study is described rather than over-claimed.

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorPresent on pituitary somatotroph cells
Signal pathwayGs, cyclic AMP, protein kinase ASequence follows receptor activation
Main measured effectGrowth hormone releaseInsulin-like growth factor 1 shifts indirectly
Half-life, binding formSeveral daysExtended through serum albumin association
Half-life, unmodified formAbout 30 minutesLimited mainly by enzymatic cleavage

Background and Molecular Design

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Related pages on this site

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

CJC-1295 Structure And Mechanism

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Reference notes

== Early life and education == Robert Finnigan was born on May 27, 1927, in Buffalo, New York, to Charles M. and Marie F. Finnigan. He was one of seven children, who were raised primarily by their father after their mother's early death. Finnigan entered the United States Naval Academy in Annapolis, Maryland, in June 1945, graduating in 1949 with a Bachelor of Science. On April 1, 1950, he married Bette Earl Van Horn at Perrin Air Force Base in Sherman, Texas. The couple had met while he was at Tyndall Air Force Base near Panama City, Florida. Because of his strong interest and aptitude in electrical engineering, he was able to enroll in an Air Force Institute of Technology program that sent qualified officers to graduate school. In 1952, he entered the University of Illinois at Urbana–Champaign, receiving an M.S. in electrical engineering in 1954 and a Ph.D. in electrical engineering in 1957. His master's thesis work with Edward C. Jordan used the ILLIAC to solve complex mathematical functions in antenna theory. For his Ph.D. he researched servomechanism theory with Gilbert Fett, completing the thesis Transient Analysis of Non-Linear Servomechanisms Using Describing Functions with Root-Locus Techniques.

The Nobel Prize committee in 1923 credited the practical extraction of insulin to a team at the University of Toronto and awarded the Nobel Prize to two men: Frederick Banting and John Macleod. They were awarded the Nobel Prize in Physiology or Medicine in 1923 for the discovery of insulin. Banting, incensed that Best was not mentioned, shared his prize with him, and Macleod immediately shared his with James Collip. The patent for insulin was sold to the University of Toronto for one dollar. Two other Nobel Prizes have been awarded for work on insulin. British molecular biologist Frederick Sanger, who determined the primary structure of insulin in 1955, was awarded the 1958 Nobel Prize in Chemistry. Rosalyn Sussman Yalow received the 1977 Nobel Prize in Medicine for the development of the radioimmunoassay for insulin. Several Nobel Prizes also have an indirect connection with insulin. George Minot, co-recipient of the 1934 Nobel Prize for the development of the first effective treatment for pernicious anemia, had diabetes. William Castle observed that the 1921 discovery of insulin, arriving in time to keep Minot alive, was therefore also responsible for the discovery of a cure for pernicious anemia. Dorothy Hodgkin was awarded a Nobel Prize in Chemistry in 1964 for the development of crystallography, the technique she used for deciphering the complete molecular structure of insulin in 1969.

Tropaeolum tuberosum (mashua, see below for other names) is a species of flowering plant in the family Tropaeolaceae, grown in the Andes, particularly in Peru and Bolivia, and to a lesser extent in Ecuador as well as in some areas of Colombia, for its edible tubers, which are eaten cooked or roasted as a vegetable. It is a minor food source, especially for native Amerindian populations. Mashua is a herbaceous perennial climber growing to 2–4 m (7–13 ft) in height. It is related to garden nasturtiums, and is occasionally cultivated as an ornamental for its brightly coloured tubular flowers. The leaves are peltate, roundly five-lobed with a petiole that twines weakly but is not truly a tendril. The root is tuberous.

==== Plastoglobuli ==== Plastoglobuli (singular plastoglobulus, sometimes spelled plastoglobule(s)), are spherical bubbles of lipids and proteins about 45–60 nanometers across. They are surrounded by a lipid monolayer. Plastoglobuli are found in all chloroplasts, but become more common when the chloroplast is under oxidative stress, or when it ages and transitions into a gerontoplast. Plastoglobuli also exhibit a greater size variation under these conditions. They are also common in etioplasts, but decrease in number as the etioplasts mature into chloroplasts. Plastoglobuli contain both structural proteins and enzymes involved in lipid synthesis and metabolism. They contain many types of lipids including plastoquinone, vitamin E, carotenoids and chlorophylls. Plastoglobuli were once thought to be free-floating in the stroma, but it is now thought that they are permanently attached either to a thylakoid or to another plastoglobulus attached to a thylakoid, a configuration that allows a plastoglobulus to exchange its contents with the thylakoid network. In normal green chloroplasts, the vast majority of plastoglobuli occur singularly, attached directly to their parent thylakoid. In old or stressed chloroplasts, plastoglobuli tend to occur in linked groups or chains, still always anchored to a thylakoid. Plastoglobuli form when a bubble appears between the layers of the lipid bilayer of the thylakoid membrane, or bud from existing plastoglobuli—though they never detach and float off into the stroma.

Sources: en.wikipedia.org

Notes from published material

It has the potential of enhancing protein tyrosine phosphorylation, which takes place during capacitation, and its effects are inhibited in the presence of lidocaine and tetrodotoxin. Veratridine has not been reported to have any effect on the acrosome reaction on its own, but it is able to block the progesterone-induced acrosome reaction. Moreover, veratridine has the effect of turning the membrane potential to a more positive one and also modifies the effect of progesterone on [Ca2+]i and sperm membrane potential. The activation of Nav1.8 is a key point in Veratradine's mechanism of action and, consequently, this sodium ion channel coordinates the effects of this compound. Veratradine also activates additional NaV channels. These facts contribute to support the importance of these Veratradine-sensitive proteins in the regulation of mature sperm function, such as human sperm fertility acquisition regulating motility, capacitation and the progesterone-induced acrosome reaction. Veratridine has been synthetically modified to introduce a photoswitchable azobenzene group (azoveratridine) that allows controlling the NaV potentiating activity with light in neurons and cardiac cells. Using this method, further late-stage modifications are possible, including the introduction of fluorescent and radioactive tags.

In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly. Myopathy means muscle disease (Greek : myo- muscle + patheia -pathy : suffering). This meaning implies that the primary defect is within the muscle, as opposed to the nerves ("neuropathies" or "neurogenic" disorders) or elsewhere (e.g., the brain). This muscular defect typically results in myalgia (muscle pain), muscle weakness (reduced muscle force), or premature muscle fatigue (initially normal, but declining muscle force). Muscle cramps, stiffness, spasm, and contracture can also be associated with myopathy. Myopathy experienced over a long period (chronic) may result in the muscle becoming an abnormal size, such as muscle atrophy (abnormally small) or a pseudoathletic appearance (abnormally large). Capture myopathy can occur in wild or captive animals, such as deer and kangaroos, and leads to morbidity and mortality. It usually occurs as a result of stress and physical exertion during capture and restraint. Muscular disease can be classified as neuromuscular or musculoskeletal in nature. Different myopathies may be inherited, infectious, non-communicable, or idiopathic (cause unknown). The disease may be isolated to affecting only muscle (pure myopathy), or may be part of a systemic disease as is typical in mitochondrial myopathies.

Sodium carbonate (soda) was produced by the Leblanc process until 1880, when the much cheaper Solvay process became available. BASF ceased to make its own and bought it from the Solvay company thereafter.

=== Genome size === Genome size is a fundamental characteristic of an organism. Ants have been found to have tiny genomes, with the evolution of genome size suggested to occur through loss and accumulation of non-coding regions, mainly transposable elements, and occasionally by whole genome duplication. This may be related to colonisation processes, but further studies are needed to verify this.

In another study, the combination of positively charged peptide amphiphiles and negatively charged long biopolymers led to the formation of hierarchically ordered membranes. When the two solutions are brought into contact, electrostatic complexation between the components of each solution creates a diffusion barrier that prevents the mixing of the solutions. Over time, an osmotic pressure difference drives the reptation of polymer chains through the diffusion barrier into the peptide amphiphile compartment, leading to the formation of fibers perpendicular to the interface that grow over time. These materials can be made in the form of flat membranes or as spherical sacs by dropping one solution into the other. These materials are robust enough to handle mechanically and a range of mechanical properties can be accessed by altering growth conditions and time. They can incorporate bioactive peptide amphiphiles, encapsulate cells and biomolecules, and are biocompatible and biodegradable.

Sources: en.wikipedia.org

Further detail

Aeromonas infection African tick bite fever American tick bite fever (Rickettsia parkeri infection) Arcanobacterium haemolyticum infection Bacillary angiomatosis Bejel (endemic syphilis) Blastomycosis-like pyoderma (pyoderma vegetans) Blistering distal dactylitis Botryomycosis Brill–Zinsser disease Brucellosis (Bang's disease, Malta fever, undulant fever) Bubonic plague Bullous impetigo Cat scratch disease (cat scratch fever, English–Wear infection, inoculation lymphoreticulosis, subacute regional lymphadenitis) Cellulitis Chancre Chancroid (soft chancre, ulcus molle) Chlamydial infection Chronic lymphangitis Chronic recurrent erysipelas Chronic undermining burrowing ulcers (Meleney gangrene) Chromobacteriosis infection Condylomata lata Cutaneous actinomycosis Cutaneous anthrax infection Cutaneous C.

==== Short-term ==== Acute adverse effects are usually the result of high or multiple doses, although single dose toxicity can occur in susceptible individuals. The most serious short-term physical health risks of MDMA are hyperthermia and dehydration. Cases of life-threatening or fatal hyponatremia (excessively low sodium concentration in the blood) have developed in MDMA users attempting to prevent dehydration by consuming excessive amounts of water without replenishing electrolytes. The immediate adverse effects of MDMA use can include:

== Cast == Karl Urban as Dredd: A famed and feared Judge. Producer Allon Reich described Dredd as "an extreme character, and he administers justice with an extreme lack of prejudice". Urban approached the producers about joining the film. He found the role challenging because the character never removes his helmet, requiring Urban to convey emotion without using his eyes. He viewed the character as an average man with an insanely tough job in a fragmenting society and likened Dredd's heroism to that of a fireman. The role also demanded physical preparation; Urban undertook intensive physical training to become a "beast of a man". He also underwent weapons and technical training to learn how to operate under fire, arrest criminals and breach doors. He insisted on performing his own motorcycle stunts for the film. He played Dredd with a raspy and harsh vocal tone akin to "a saw cutting through bone", which he found difficult to sustain.

==== Reduced experimental footprint ==== One of the core advantages of digital microfluidics, and of microfluidics in general, is the use and actuation of picoliter to microliter scale volumes. Workflows adapted from the bench to a DMF system are miniaturized, meaning working volumes are reduced to fractions of what is normally required for conventional methods. For example, Thaitrong et al. developed a DMF system with a capillary electrophoresis (CE) module with the purpose of automating the process of next generation sequencing (NGS) library characterization. Compared to an Agilent BioAnalyzer (an instrument commonly used to measure sequencing library size distribution), the DMF-CE system consumed ten-fold less sample volume. Reducing volumes for a workflow can be especially beneficial if the reagents are expensive or when manipulating rare samples such as circulating tumor cells and prenatal samples. Miniaturization also means a reduction in waste product volumes.

==== Phase 1 ==== For the first phase, the WHO formed a team of ten researchers with expertise in virology, public health and animals to conduct a thorough study. One of the team's tasks was to retrospectively ascertain what wildlife was being sold in local wet markets in Wuhan. The WHO's phase one team arrived and quarantined in Wuhan, Hubei, China in January 2021. Members of the team included Thea Fisher, John Watson, Marion Koopmans, Dominic Dwyer, Vladimir Dedkov, Hung Nguyen-Viet, Fabian Leendertz, Peter Daszak, Farag El Moubasher, and Ken Maeda. The team also included five WHO experts led by Peter Ben Embarek, two Food and Agriculture Organization representatives, and two representatives from the World Organisation for Animal Health. The inclusion of Peter Daszak in the team stirred controversy. Daszak is the head of EcoHealth Alliance, a nonprofit that studies spillover events, and has been a longtime collaborator of over 15 years with Shi Zhengli, Wuhan Institute of Virology's director of the Center for Emerging Infectious Diseases. While Daszak is highly knowledgeable about Chinese laboratories and the emergence of diseases in the area, his close connection with the WIV was seen by some as a conflict of interest in the WHO's study. When a BBC News journalist asked about his relationship with the WIV, Daszak said, "We file our papers, it's all there for everyone to see." The team was denied access to raw data, including the list of early patients, swabs, and blood samples. It was allowed only a few hours of supervised access to the Wuhan Institute of Virology.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

How does the albumin-binding group alter behavior?

It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.

What do studies generally measure?

Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network